Respiratory Exacerbations and Lung Function Decline in People with Smoking History and Normal Spirometry.

Fortis S, Strand M, Bhatt SP, Ten Eyck P, Wendt L, Parekh T, Han MK, Hokanson JE, Kinney G, Curtis JL, Bowler RP, Wan ES, Kunisaki KM, Wendt CH, Regan E, Dransfield M, Crapo JD, Silverman EK, Comellas AP. Respiratory Exacerbations and Lung Function Decline in People with Smoking History and Normal Spirometry. American journal of respiratory and critical care medicine. 2025 Feb 13 DOI: 10.1164/rccm.202401-0023OC.

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information vaww.hsrd.research.va.gov/dimensions/

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.    Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions

Search for Abstract from PubMed

---

Abstract:

RATIONALE: The impact of respiratory exacerbation on chronic obstructive pulmonary disease (COPD) is well established. The effects of respiratory exacerbations in people with cigarette smoking but normal spirometry are unknown. OBJECTIVE: To assess the association of respiratory exacerbations with lung function decline and mortality in people with normal spirometry and current or former cigarette smoking history. METHODS: We analyzed data from COPDGene participants with 10 pack-years cigarette smoking and normal spirometry at enrollment (Visit 1) defined as post-bronchodilator forced expiratory volume in 1 second (FEV)/forced vital capacity (FVC) lower limit of normal (LLN) and FEV LLN. We examined whether respiratory exacerbations occurring between Visits 1 and the 5-year follow-up visit (Visit 2) were associated with FEV decline, and all-cause mortality. MEASUREMENTS AND MAIN RESULTS: Among 2,939 participants with cigarette smoking history and normal lung function at Visit 1, each additional exacerbation between visit 1 and 2 was associated with a 2.96 ml/year FEV decline (95%CI 1.81 to 4.12; P < 0.001) at Visit 2. Experiencing 1 severe exacerbation between Visits 1 and 2 was associated with 14.6 ml/year FEV decline relative to those with no severe exacerbations (95% CI 8.56 to 20.6; P < 0.001). Individuals with 1 severe exacerbation between Visits 1 and 2 had increased mortality compared to those with no severe exacerbations (17.1% vs. 9.8%; adjusted hazard ratio 1.97;95% CI 1.40 to 2.77; P < 0.001). CONCLUSIONS: Respiratory exacerbations in people with cigarette smoking but normal spirometry were associated lung function decline. Experiencing a severe respiratory exacerbation was associated with increased mortality.